Jason Snipe, CIO, Odyssey Capital Advisors

Just bought it this week. Really likes them buying Signify, a home healthcare business as the population ages. CVS boasts a 13% cash flow yield and pays a 2% dividend.

Definitely a hold but a core holding. Their earnings report wasn't great as it faces lots of headwinds like a strong US dollar. But they are innovative and way ahead of its peers.

Lots of demand for industrial gases and long-term projects still on the books.

Shares are down 50% off highs and an analyst today sees even more downside because a large segment of chips are used in gaming and crypto mining Is not shocked by their latest numbers. Gaming saw a jump in demand during Covid, and now the stock is in normalization mode. They missed on revenues and earnings, but data centre numbers were up--that's resilient. Will be volatility short term. They remain an innovative company, so he's holding long term and will buy on dips.

Powell's hawkish comments today Clearly, Powell was forceful in saying the Fed will stifle demand. There's been so much free money in markets, so Powell had to say what he said today--will keep rates up to beat inflation.

Likes energy period. Free cash flow yield of over 11%. Strong last quarter. Stay long.

Posted records profits today. Shares are surging today and so far this year. Nice top and bottom line beats and return on capital of 26% as they reduced debt below 15%. Also, they raised their share buyback. The oil supply/demand imbalance won't change for a while.

He just sold his Walmart. The news earlier this week cut guidance for full-year 2023. There's a shift on consumer sentiment. It trades at a forward 22x which is a premium to the market. That's why he sold. WM will figure things out but will take a quarter or two.

Amazon is a better play as it continues to take market share from Walmart. Amazon's e-commerce is stronger, of course.

Staples are up YTD, but struggled in the past month. P&G's organic sales are slowing, 10% last quarter, 7% this, and guiding 3-5%. Shutdowns in China, high USD and reduced operations in Russia are reasons. 50% of sales are overseas so the strong dollar is headwind.

Struggling today after earnings. Organic sales did surprise, up 10%, while Latin American growth was over 12%. But multinationals with lots of overseas exposure will struggle against the high USD.

A great name in pharma that reported today. Their neuroscience division is up 14% quarter over quarter, while cash flow yield is above 7%. It's performed relatively well vs. the market YTD. He still likes the name.

It's down 74% off its peak, 54% YTD, a struggle. Let's see if this activist investor comes in and what he does. He does love their business model. Will watch the next few quarters.

Down 30% YTD, a struggle. Macau reopening is a focus, but he's watching Bet MGM, which is nice catalyst. They report next week.

It's struggling, down 70% YTD. There are some strategic growth opportunities, but he has weak expectations for their report next week.